Robert Glassman Sells 8,667 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 8,667 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $38.27, for a total transaction of $331,686.09. Following the sale, the director owned 10,500 shares in the company, valued at $401,835. The trade was a 45.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Robert Glassman also recently made the following trade(s):

• On Wednesday, September 9th, Robert Glassman sold 8,000 shares of Pharvaris stock. The shares were sold at an average price of $37.55, for a total transaction of $300,400.00.

Pharvaris Stock Performance

Shares of Pharvaris stock traded up $0.95 on Thursday, reaching $38.50. 236,024 shares of the stock were exchanged, compared to its average volume of 404,961. The firm has a market cap of $2.52 billion, a PE ratio of -12.62 and a beta of -2.33. The firm’s 50 day moving average is $35.31 and its 200-day moving average is $31.63. Pharvaris N.V. has a one year low of $20.65 and a one year high of $43.25.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, equities research analysts expect that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

Large investors have recently bought and sold shares of the company. venBio Partners LLC bought a new stake in shares of Pharvaris during the second quarter worth about $160,569,809. Wellington Management Group LLP boosted its position in Pharvaris by 12.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock worth $82,748,000 after buying an additional 274,034 shares during the period. Commodore Capital LP boosted its position in Pharvaris by 1.6% during the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after buying an additional 29,525 shares during the period. 5AM Venture Management LLC bought a new stake in Pharvaris during the 2nd quarter worth approximately $27,581,008. Finally, Seven Fleet Capital Management LP increased its position in Pharvaris by 144.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock valued at $26,782,000 after acquiring an additional 457,804 shares during the period.

Wall Street Analyst Weigh In

PHVS has been the subject of several recent analyst reports. UBS Group set a $79.00 price objective on Pharvaris in a research report on Wednesday, September 9th. Wells Fargo & Company boosted their target price on Pharvaris from $55.00 to $65.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 9th. Leerink Partners increased their target price on shares of Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a research note on Tuesday, September 8th. Finally, Wedbush upped their price objective on shares of Pharvaris from $42.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Pharvaris has a consensus rating of “Moderate Buy” and an average target price of $59.87.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.